Emerging in the arena of weight management therapy, retatrutide presents a distinct approach. Unlike many available medications, retatrutide functions as a dual agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. This concurrent engagement promotes several beneficial effects,